Curis regains Nasdaq bid price compliance

Curis, Inc. reports that on July 24, 2026 it received written notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the bid price requirement, and is in full compliance with conditions set by a Nasdaq Hearings Panel.

Rhea-AI Filing Summary

Curis, Inc. reports that on July 24, 2026 it received written notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the bid price requirement, and is in full compliance with conditions set by a Nasdaq Hearings Panel.

Under Listing Rule 5815(d)(4)(A), Curis will be subject to a one-year Discretionary Panel Monitor starting July 24, 2026. If Curis fails to meet any continued listing requirement during this period, Nasdaq Staff will issue a Delist Determination Letter and the company must promptly request a new hearing before a Hearings Panel. During the monitor period Curis cannot submit a compliance plan and Staff cannot grant additional time to regain compliance. The company notes there can be no assurance that any appeal would succeed or that its stock will remain listed on Nasdaq, and it includes forward-looking statement cautions referencing risk factors in its Form 10-K for the year ended December 31, 2025.

Positive

• Regains Nasdaq bid price compliance, with Nasdaq confirming on July 24, 2026 that Curis meets Listing Rule 5550(a)(2) and is in full compliance with prior Hearings Panel conditions, reducing immediate delisting pressure.

Negative

• One-year heightened Nasdaq monitoring under a Discretionary Panel Monitor starting July 24, 2026, with any new deficiency triggering an automatic Delist Determination Letter and no opportunity to submit a compliance plan or obtain extra time.
• Ongoing delisting risk, as Curis explicitly states there can be no assurance that any future appeal will be successful or that its shares will remain listed on Nasdaq.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Bid Price Rule: Nasdaq Listing Rule 5550(a)(2) Monitor period: one-year period from July 24, 2026 Appeals framework: Listing Rules 5815(d)(4)(A) and 5810(c)(2)

3 metrics

Bid Price Rule Nasdaq Listing Rule 5550(a)(2) Rule with which Curis regained compliance on July 24, 2026

Monitor period one-year period from July 24, 2026 Duration of Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A)

Appeals framework Listing Rules 5815(d)(4)(A) and 5810(c)(2) Govern monitoring and limits on compliance plans and extensions during the monitor period

Key Terms

Nasdaq Listing Rule 5550(a)(2), Discretionary Panel Monitor, Delist Determination Letter, forward-looking statements

4 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”)"

Discretionary Panel Monitor regulatory

"subject to a Discretionary Panel Monitor for a one-year period from July 24, 2026"

A discretionary panel monitor is a compliance mechanism—either a small oversight group or a software tool—that reviews and checks trades made at a manager’s discretion to ensure they follow investment rules, risk limits and client instructions. For investors it matters because this watchdog helps prevent unauthorized or risky decisions, reduces the chance of loss or regulatory penalties, and protects trust much like a referee or speed governor keeps a game or machine within safe limits.

Delist Determination Letter regulatory

"the Staff will issue a Delist Determination Letter, and the Company promptly schedule a new hearing"

A delist determination letter is a formal notice from a stock exchange telling a company it no longer meets listing rules and is facing removal from the exchange. For investors, it signals that the stock may lose its regular trading venue, which can sharply reduce liquidity and visibility—like being forced out of a busy shopping mall into a small flea market—raising the risk of price drops and harder-to-sell shares.

forward-looking statements financial

"contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Curis (CRIS) announce about its Nasdaq listing status?

Curis announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2) for bid price as of July 24, 2026 and is now in full compliance with conditions previously set by a Nasdaq Hearings Panel.

What is the one-year Discretionary Panel Monitor for Curis (CRIS)?

Nasdaq placed Curis under a one-year Discretionary Panel Monitor beginning July 24, 2026. During this period, any new listing deficiency leads directly to a Delist Determination Letter, escalating oversight of the company’s continued listing status.

What happens if Curis (CRIS) fails a Nasdaq listing requirement during the monitor period?

If Curis fails any continued listing requirement during monitoring, Nasdaq Staff will issue a Delist Determination Letter. Curis must then promptly request a new hearing, which may be oral or written, before the initial or a newly convened Hearings Panel.

Can Curis (CRIS) submit a plan to regain compliance during the monitor period?

No. During the one-year Discretionary Panel Monitor, Curis is not permitted to provide Nasdaq Staff with a plan of compliance for any new deficiency, and Staff cannot grant additional time to regain compliance under Rule 5810(c)(2).

Does Curis (CRIS) guarantee it will remain listed on Nasdaq?

Curis explicitly states there can be no assurance that any appeal during the monitor period will be successful or that its securities will remain listed on Nasdaq, highlighting ongoing listing and compliance risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 04:02 PM Accepted by SEC EDGAR 07/30/2026 - 04:01 PM Learn about SEC filing dates

0001108205false00011082052026-07-242026-07-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): July 24, 2026

Curis, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware			000-30347			04-3505116
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

128 Spring Street, Building C - Suite 500, Lexington MA 02421

(Address of Principal Executive Offices) (Zip Code)

(617) 503-6500

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:        

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.01 per share

CRIS

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 24, 2026, Curis, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel (the “Panel”).

Pursuant to Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for a one-year period from July 24, 2026. If the Company fails to maintain compliance with any continued listing requirement, the Staff will issue a Delist Determination Letter, and the Company promptly schedule a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The hearing may be oral or written, at the Company’s election. Notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide Staff with a plan of compliance with respect to any deficiency that arises during the monitor period, and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to any deficiency. The Hearings Panel will consider the Company’s compliance history when rendering its decision. However, there can be no assurance that such appeal will be successful or that the Company will remain listed on Nasdaq.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, any statements with respect to the Company’s ability to maintain compliance with Nasdaq Listing Rules or remain listed on Nasdaq. The words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "continue," "potential," "focus," "strategy," "mission," or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from those in these forward-looking statements include, but are not limited to, risks referenced in Item 1A, “Risk Factors” of Part I of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by the other filings that the Company periodically makes with the SEC. In addition, any forward-looking statements represent the views of the Company only as of the date of the Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any intention or obligation to update these forward-looking statements in the future to reflect events, information, or circumstances after the date hereof, except as may be required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Curis, Inc.
Date:			July 30, 2026			By:			/s/ Diantha Duvall
									Diantha Duvall
									Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.9 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.3 KB